← Eichor
Condition: Relapsed Refractory B Cell Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Relapsed Refractory B Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
Phase 1/Phase 2 · 2 location(s) · Uppsala University · NCT06002659Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
Phase 2 · 1 location(s) · Ruijin Hospital · NCT05348213Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Phase 1 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06464861Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Phase 2 · 1 location(s) · Hrain Biotechnology Co., Ltd. · NCT05436223Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
Phase 1/Phase 2 · 1 location(s) · Fondazione Matilde Tettamanti Menotti De Marchi Onlus · NCT05869279A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
Phase 1 · 1 location(s) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · NCT07093073A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Phase 1/Phase 2 · 15 location(s) · Shanghai AbelZeta Ltd. · NCT05800977A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants
Phase 1/Phase 2 · 30 location(s) · Hoffmann-La Roche · NCT05533775Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and
Phase 1/Phase 2 · 26 location(s) · Sellas Life Sciences Group · NCT04588922AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Phase 1/Phase 2 · 80 location(s) · AstraZeneca · NCT06137118Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Phase 2 · 104 location(s) · SWOG Cancer Research Network · NCT05890352Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06682130Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
Phase 1/Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06838832A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel The
Phase N/A · 21 location(s) · AstraZeneca · NCT07065344CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
Phase 1 · 1 location(s) · Aibin Liang，MD，Ph.D. · NCT06734871A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06446128Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07538635Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT06326008B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide
Phase 1 · 1 location(s) · Mayo Clinic · NCT06191887Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Zhujiang Hospital · NCT06902012A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgki
Phase 1 · 16 location(s) · Sanofi · NCT06392477Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 2 location(s) · Samsung Medical Center · NCT06552559An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase 1 · 1 location(s) · Fudan University · NCT06517004CAV Regimen for R/R Ph- B-ALL
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT05657652
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.